Author/Authors :
Khooshemehri, Paniz Medical Genomics Research Center - Tehran Medical Sciences - Islamic Azad University - Tehran, Iran , Jamaldini, Hamid Personalized Medicine Research Center - Endocrinology and Metabolism Clinical Sciences Institute - Tehran University of Medical Sciences - Tehran, Iran , Ziaei, Amir Mohsen Urology and Nephrology Research Center - Shahid Labbafinejad Medical Center - Shahid Beheshti University of Medical Sciences - Tehran, Iran , Afshari, Mahdi Department of Community Medicine - Zabol University of Medical Sciences - Zabol, Iran , Sattari, Mahshid Medical Genomics Research Center - Tehran Medical Sciences - Islamic Azad University - Tehran, Iran , Narouie, Behzad Department of Urology - Zahedan University of Medical Sciences - Zahedan, Iran , Sotoudeh, Mehdi Urology and Nephrology Research Center - Shahid Labbafinejad Medical Center - Shahid Beheshti University of Medical Sciences - Tehran, Iran , Montazeri, Vahideh Department of Toxicology and Pharmacology - Faculty of Pharmacy - Tehran University of Medical Science - Tehran, Iran , Sarhangi, Negar Personalized Medicine Research Center - Endocrinology and Metabolism Clinical Sciences Institute - Tehran University of Medical Sciences - Tehran, Iran , Hasanzad, Mandana Personalized Medicine Research Center - Endocrinology and Metabolism Clinical Sciences Institute - Tehran University of Medical Sciences - Tehran, Iran
Abstract :
Purpose: Mismatch repair (MMR) is one of the DNA repair systems that correct mispaired bases during DNA replication errors. Polymorphisms in genes can increase susceptibility to the development of prostate cancer (PCa). In this study, we investigated mutL homolog 1 (MLH93- )1G>A (rs1800734) and mutS homolog 3 (MSH3) (rs26279) polymorphisms with the risk of PCa.
Materials and Methods: In this study of Iranian population, 175 histopathologically confirmed (PCa) patients and
230 benign prostate hyperplasia (BPH) as the controls were recruited. The genotypes of MLH1 and MSH3 were
determined by polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP) method.
Results: There was no significant difference of MLH1 (P = 0.4) and MSH3 (P = 0.5) genotype distributions among
PCa cases and controls. and also patients with PCa were not significant differences compared to those without in
stage of cancer, grade of tumor, perineural invasion, and vascular invasion.
Conclusion: Our results did not show adequate evidence for any significant association of MLH1 and MSH3 polymorphisms and PCa .
Keywords :
prostate cancer , MSH3 , MLH1 , polymorphism , PCR-RFLP
